Advertisement

Prevalence of antibodies to hepatitis C virus in patients with hepatocellular carcinoma in Austria

  • Martina Baur
  • U. Hay
  • G. Novacek
  • C. Dittrich
  • P. Ferenci
Part of the Archives of Virology book series (ARCHIVES SUPPL, volume 4)

Summary

In 12 of 54 (22%) patients with histologically verified hepatocellular carcinoma, antibodies to hepatitis C virus were found. In patients with hepatocellular carcinoma the frequency of anti-hepatitis C virus positivity was similar whether cirrhosis (6 of 22 patients (27%)) was present or not (2 of 15 (13%)). Out of 54, 23 patients (43%) were negative both for hepatitis B or C markers. Out of 53,22 (42%) had positive hepatitis B markers, 8 of 22 were HBsAg positive. Patients with hepatocellular carcinoma and cirrhosis had a higher percentage of hepatitis B virus markers than patients with cirrhosis without hepatocellular carcinoma. Out of 70 patients with cirrhosis but without hepatocellular carcinoma, 24 (34%) had antibodies to hepatitis C virus. Our data of similar frequencies of antibodies to hepatitis C virus in patients with hepatocellular carcinoma or with liver cirrhosis but without hepatocellular carcinoma indicate that at least in Austrian patients, hepatitis C virus infections are not an important factor for development of hepatocellular carcinoma.

Keywords

Hepatocellular Carcinoma Liver Cirrhosis Austrian Patient nonB Hepatitis Serum Globulin Concentration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Beasley RP, Hwang Lu-Yu, Lin GC, Chien CS (1981) Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet ii: 1129–1133CrossRefGoogle Scholar
  2. 2.
    Bruix J, Calvet X, Costa J, Ventura M, Bruguera M, Castillo R, Barrera JM, Ercilla G, Sanchez-Tapias JM, Vall M, Bru C, Rodes J (1989) Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet ii: 1004–1006CrossRefGoogle Scholar
  3. 3.
    Chiaramonte M, Farinati F, Fagiuoli S, Ongaro S, Aneloni V, De Maria N, Naccarato R (1990) Lancet 335: 301–302Google Scholar
  4. 4.
    Colombo M, Choo QL, Ninno ED, Dioguardi N, Kuo G, Donato MF, Tommasini MA, Houghton M (1989) Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet ii: 1006–1008CrossRefGoogle Scholar
  5. 5.
    Dazza MC, Meneses LV, Girard PM, Villaroel C, Brechot C, Larouzet B (1990) Hepatitis C virus antibody and hepatocellular carcinoma. Lancet 335: 1216Google Scholar
  6. 6.
    Ducreux M, Dussaix E, Briantais MJ, Jacques L, Buffet C, Pelletier G, Yvart J, Etienne LP (1990) Lancet 335: 301Google Scholar
  7. 7.
    Ferenci P, Dragosics B, Marosi L, Kiss F (1984) Relative incidence of primary liver cancer in cirrhosis in Austria. Etiological considerations. Liver 4: 7–14Google Scholar
  8. 8.
    Johnson PJ, Williams R (1990) Hepatitis C antibodies and hepatocellular carcinoma: new clues or a false trial? Editorial, J Natl Cancer Inst 82: 986–987PubMedCrossRefGoogle Scholar
  9. 9.
    Kew MC, Houghton M, Choo QL, Kuo G (1990) Hepatitis C virus antibodies in southern African blacks with hepatocellular carcinoma. Lancet 335: 873–874PubMedCrossRefGoogle Scholar
  10. 10.
    Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakamo Y, Furuta S, Akahane Y, Nishioka K, Purcell RH, Alter H J (1990) Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 12: 671–675PubMedCrossRefGoogle Scholar
  11. 11.
    Levrero M, Tagger A, Balsano C, Marzio ED, Avantaggiati ML, Natoli G, Diop D, Villa E, Diodati G, Alberti A (1991) Antibodies to hepatitis C virus in patients with hepatocellular carcinoma. J Hepatol 12: 60–63PubMedCrossRefGoogle Scholar
  12. 12.
    Li JS, Tong SP, Vitvitski L, Trepo C (1992) Sequence analysis of PCR amplified hepatitis C virus cDNA from French non-A, non-B hepatitis patients. In: De Bac C, Gerlich WH, Taliani G (eds) Chronically evolving viral hepatitis. Springer, Wien, New York (Arch Virol, Suppl 4, pp 184–185)CrossRefGoogle Scholar
  13. 13.
    Munoz N, Bosch X (1987) Epidemiology of hepatocellular carcinoma. In: Okuda K, Ishak KG (eds) Neoplasms of the liver. Springer, Berlin Heidelberg New York Tokyo, pp 3–19Google Scholar
  14. 14.
    Sbolli G, Zanetti AR, Tanzi E, Cavanna L, Civardi G, Fornari F, Di Stasi M, Buscarini L (1990) Serum antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. J Med Virol 30: 230–232PubMedCrossRefGoogle Scholar
  15. 15.
    Simonetti RG, Cottone M, Craxi A, Pagliaro L, Rapicetta M, Chionne P, Costatino A (1989) Prevalence of antibodies to hepatitis C virus in hepatocellular carcinoma. Lancet ii: 1338CrossRefGoogle Scholar
  16. 16.
    Weiss W (1984) Das primäre Leberkarzinom. Facultas, Wien, p 45Google Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • Martina Baur
    • 1
  • U. Hay
    • 2
  • G. Novacek
    • 1
  • C. Dittrich
    • 3
  • P. Ferenci
    • 1
  1. 1.I. Department of Gastroenterology and HepatologyUniversity of ViennaWienAustria
  2. 2.II. Department of Gastroenterology and HepatologyUniversity of ViennaAustria
  3. 3.Department of ChemotherapyUniversity of ViennaWienAustria

Personalised recommendations